680
Participants
Start Date
October 31, 2009
Primary Completion Date
May 11, 2023
Study Completion Date
May 11, 2023
Rituximab
Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).
Cyclophosphamide
Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
Vincristine
Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.
Prednisolone
Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
Fludarabine
Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
Aberdeen Royal Infirmary, Aberdeen
Ysbyty Gwynedd, Bangor
Birmingham Heartlands, Birmingham
Royal Bournemouth Hospital, Bournemouth
Bradford Royal Infirmary, Bradford
Frenchay Hospital, Bristol
Queen's Hospital, Burton, Burton-on-Trent
Addenbrookes Hospital, Cambridge
Kent and Canterbury Hospital, Canterbury
Velindre Hospital, Cardiff
Countess of Chester, Chester
Leighton Hospital, Crewe
Trafford General Hospital, Davyhulme
Russels Hall Hospital, Dudley
Royal Devon & Exeter Hospital, Exeter
Falkirk & District Royal Infirmary, Falkirk
Queen Elizabeth Hospital, Gateshead
Medway Maritime Hospital, Gillingham
Beatson Oncology Centre, Glasgow
Royal Alexandra Hospital, Glasgow
Harrogate District Foundation Trust, Harrogate
Northwick Park Hospital, Harrow
Princess Royal Hospital, Bromley, Hayes
Huddersfield Royal Infirmary, Huddersfield
Castle Hill Hospital, Hull
Raigmore Hospital,, Inverness
Ipswich Hospital, Ipswich
Kettering General Hospital, Kettering
The Queen Elizabeth Hospital, Kings Lynn, Kings Lynn
St James University Hospital, Leeds
Leicester Royal Infirmary, Leicester
Royal Liverpool University Hospital, Liverpool
University Hospital Aintree, Liverpool
Guys & St Thomas Hospital, London
Kings College Hospital, London
Royal Free Hospital, London
St Bartholomews Hospital, London
University College Hospital, London
Altnagelvin Hospital, Londonderry
Luton & Dunstable Hospital, Luton
Kent Oncology Centre, Maidstone
Manchester Royal Infirmary, Manchester
The Christie Hospital, Manchester
Arrowe Park Hospital, Metropolitan Borough of Wirral
Royal Victoria Infirmary, Newcastle upon Tyne
Northampton General Hospital, Northampton
Mount Vernon Hospital, Northwood
Nottingham City Hospital, Nottingham
Derriford Hospital, Plymouth
Whiston Hospital, Prescot
Queens Hospital, Romford
Salford Royal Hospital, Salford
Salisbury District Hospital, Salisbury
Diana Princess of Wales Hospital, Scunthorpe
Royal Hallamshire Hospital, Sheffield
Wexham Park Hospital, Slough
South Tyneside District General Hospital, South Shields
Basingstoke and North Hampshire Hospital, Southampton
Southampton General Hospital, Southampton
St Richards Hospital, Southampton
Glan Clwyd Hospital, St Asaph
Stafford District General Hospital, Stafford
Lister Hospital, Stevenage
Sunderland Royal Hospital, Sunderland
Great Western Hospital, Swindon
Torbay District General Hospital, Torquay
Royal Cornwall Hospital, Truro
Hillingdon Hospital, Uxbridge
Pinderfields General Hospital, Wakefield
West Herts, Watford
Worcestershire Acute Hospitals NHS Trust, Worcester
Worthing Hospital, Worthing
York District Hospital, York
Collaborators (1)
Liverpool University Hospitals NHS Foundation Trust
OTHER_GOV
Cancer Research UK
OTHER
Roche Pharma AG
INDUSTRY
University of Liverpool
OTHER